Drug Interactions between Hetlioz LQ and rufinamide
This report displays the potential drug interactions for the following 2 drugs:
- Hetlioz LQ (tasimelteon)
- rufinamide
Interactions between your drugs
rufinamide tasimelteon
Applies to: rufinamide and Hetlioz LQ (tasimelteon)
MONITOR: Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes. When tasimelteon was administered after 11 days of treatment with the potent CYP450 inducer rifampin 600 mg/day, tasimelteon systemic exposure (AUC) decreased by approximately 90% compared to tasimelteon administered alone. No data are available for use with other, less potent inducers.
MANAGEMENT: The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.
References (1)
- (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
Drug and food interactions
rufinamide food
Applies to: rufinamide
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of rufinamide. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of rufinamide. In healthy volunteers, administration of a single 400 mg dose of rufinamide with food resulted in an approximately 56% increase in mean peak plasma concentration (Cmax) and a 34% increase in systemic exposure (AUC) compared to administration during a fasting state.
MANAGEMENT: To ensure maximal oral absorption, it is preferable to administer rufinamide with food. Patients receiving rufinamide should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how rufinamide affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (1)
- (2008) "Product Information. Banzel (rufinamide)." Eisai Inc
tasimelteon food
Applies to: Hetlioz LQ (tasimelteon)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of tasimelteon. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
ADJUST DOSING INTERVAL: Food may delay the absorption and onset of action of tasimelteon. According to the product labeling, administration of tasimelteon with a high-fat meal decreased peak plasma concentration (Cmax) by 44% and delayed the median time to reach Cmax by approximately 1.75 hours compared to administration in the fasted state.
MONITOR: Smoking induces CYP450 1A2 and may reduce the plasma concentrations of tasimelteon, which is metabolized by the isoenzyme. According to the product labeling, tasimelteon systemic exposure was approximately 40% lower in smokers than in nonsmokers.
MANAGEMENT: Patients receiving tasimelteon should be advised to avoid or limit consumption of alcohol. Tasimelteon should be taken without food. Patients who smoke may have a reduced therapeutic response to tasimelteon.
References (1)
- (2014) "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.